abn amro $3.52 valuation, page-7

mmover,

I think it's worth a lot more than that.

Bioshares put a $12.05 a share valuation on acl on 5th Aug this year.

I think most valuations vastly under-estimate the size of the market APP will command. Synthetic heparin should have approvals for all of the markets non-synthetic is. Synthetic is twice as safe & less intrusive. APP will go for the whole heparin market, not just the synthetic market. They normal get 50% to 90% of the market, and there's no reason to believe that won't happen again. Remember APP are putting money into this project, and will be paying all costs going forward within a week or so.

If acl was quoted on the nasdaq they would currently be over $10 a share, just like momenta (who aren't as good). acl will be floated on the nasdaq next year, so that's how soon this stock could become a double digit dollar stock.

All said, it's surely too cheap for a takeover attempt not to happen. Althought their partners might be able to help protect acl a bit.

all imho